Form D · Biotechnology
Syntr Health Technologies, INC
Irvine, CA · CIK 0001762296
Offering snapshot reported Sep 2, 2022 · SEC filing
- Reported sold
- $795K Indefinite offering
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $5K Reported outside-investor minimum
- First sale
- Mar 18, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 2, 2022 | Initial | $795,000 | No comparison | 6 | SEC filing |
| Jul 29, 2021 | Amendment | $2,152,000 | No comparison | Not reported | SEC filing |
| Jan 28, 2020 | Initial | $681,000 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-457832
Simple Agreement for Future Equity
Source: Form D, filed Sep 2, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Hugo Salas | Director |
| Dane Shackleford | Director |
| Ahmed Zobi | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
5270 California Ave Suite 300
Irvine, CA, 92617
Irvine, CA, 92617